[Primary central nervous lymphoma: what is the role for radiotherapy?]

Cancer Radiother. 2014 Nov;18(7):685-92. doi: 10.1016/j.canrad.2014.06.025. Epub 2014 Oct 18.
[Article in French]

Abstract

Primary central nervous system lymphoma is a rare extranodal form of non-Hodgkin lymphoma with an aggressive course and unsatisfactory outcome. Historically, whole-brain radiotherapy was the sole treatment for patients with primary central nervous system lymphoma, with high response rates but typically, this did not result in long-lasting remissions. The addition of high-dose methotrexate-based chemotherapy regimens to whole-brain radiotherapy has significantly improved patients' outcome, but has resulted in a higher incidence of late neurotoxicity, particularly in elderly patients. To date, the role of consolidation radiotherapy is controversial, and some investigators have developed alternative strategies aiming at avoiding immediate irradiation or using a reduced radiotherapy dose to the whole-brain with promising results.

Keywords: Autogreffe de cellules souches; Autologous stem cell transplantation; Chemotherapy; Chimiothérapie; Lymphome primitif du système nerveux central; Neurotoxicity; Neurotoxicité; Primary central nervous system lymphoma; Radiothérapie de l’encéphale en totalité; Whole-brain radiotherapy.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Central Nervous System Neoplasms / therapy*
  • Humans
  • Lymphoma, Non-Hodgkin / therapy*
  • Methotrexate / therapeutic use
  • Prognosis
  • Radiotherapy Dosage
  • Radiotherapy, Adjuvant
  • Stem Cell Transplantation

Substances

  • Antineoplastic Agents
  • Methotrexate